Entity Details

Primary name TIMP3_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP35625
EntryNameTIMP3_HUMAN
FullNameMetalloproteinase inhibitor 3
TaxID9606
Evidenceevidence at protein level
Length211
SequenceStatuscomplete
DateCreated1994-06-01
DateModified2021-06-02

Ontological Relatives

GenesTIMP3

GO terms

Show/Hide Table
GOName
GO:0002020 protease binding
GO:0002576 platelet degranulation
GO:0004857 enzyme inhibitor activity
GO:0005576 extracellular region
GO:0005615 extracellular space
GO:0005634 nucleus
GO:0007601 visual perception
GO:0008191 metalloendopeptidase inhibitor activity
GO:0009725 response to hormone
GO:0010033 response to organic substance
GO:0010951 negative regulation of endopeptidase activity
GO:0031012 extracellular matrix
GO:0031089 platelet dense granule lumen
GO:0034097 response to cytokine
GO:0046872 metal ion binding
GO:0051045 negative regulation of membrane protein ectodomain proteolysis
GO:0062023 collagen-containing extracellular matrix
GO:0070373 negative regulation of ERK1 and ERK2 cascade
GO:1903984 positive regulation of TRAIL-activated apoptotic signaling pathway
GO:1904684 negative regulation of metalloendopeptidase activity

Subcellular Location

Show/Hide Table
Subcellular Location
Secreted

Domains

Show/Hide Table
DomainNameCategoryType
IPR001134 Netrin domainDomainDomain
IPR001820 Protease inhibitor I35 (TIMP)FamilyFamily
IPR008993 Tissue inhibitor of metalloproteinases-like, OB-foldFamilyHomologous superfamily
IPR015612 Metalloproteinase inhibitor 3FamilyFamily
IPR027465 Proteinase inhibitor I35b (TIMP), C-terminalFamilyHomologous superfamily
IPR030490 Tissue inhibitor of metalloproteinase, conserved siteSiteConserved site

Diseases

Show/Hide Table
Disease IDSourceNameDescription
136900 OMIMSorsby fundus dystrophy (SFD)Rare autosomal dominant macular disorder with an age of onset in the fourth decade. It is characterized by loss of central vision from subretinal neovascularization and atrophy of the ocular tissues. Generally, macular disciform degeneration develops in the patients eye within 6 months to 6 years. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB05383 PimagedineDrugbanksmall molecule